-OPUL is an end-to-end, cloud-based payment
platform designed to cultivate long-term customer relationships and
optimize business operations for aesthetic practices-
Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology
company focused on innovative aesthetic and therapeutic offerings,
today announced the launch of OPUL™, the first-of-its-kind
Relational Commerce Platform that combines seamless, simple and
smart payment solutions, practice data analytics and enhanced
customer service to foster increased consumer loyalty and
retention, specifically designed for aesthetic practices in the
U.S.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20211011005200/en/
Opul - First-of-its-Kind Relational
Commerce Platform for Aesthetic Practices (Photo: Business
Wire)
Today’s aesthetic market is flooded with discounts and coupons,
driving consumers to price shop. The result for practices is a
decrease in consumer loyalty and retention. As the latest launch
from the Revance Aesthetics portfolio, OPUL™ is the solution that
replaces one-and-done transactions with a more valuable and
profitable relationship model. Early release features include:
- Practice Reporting and Analytics: Comprehensive
reporting to help aesthetic practice owners and managers understand
the health of their business with transaction and sales data across
all products and services – not limited to one brand.
- Customizable Checkout: Customizable check out options to
elevate consumer experiences, including a comprehensive catalog
concierge with access to over 6,000 aesthetic products and
services.
- Seamless and Smart Payments: OPUL operates as a
registered payment facilitator (PayFac), enabling OPUL to offer low
and transparent processing fees, which helps to increase
transaction value for the practice, and provides trackable insights
of purchasing history to help encourage reoccurring visits and
consumer loyalty.
“OPUL™ was built to address the important needs of aesthetic
practices today – optimizing patient experiences and business
outcomes through strong customer loyalty and relationships. With
almost 40,000 and growing aesthetic practices across the U.S., the
industry is hungry for innovation,” said Dustin S. Sjuts, Chief
Commercial Officer of Revance. “OPUL™ is therefore the first
technology platform in the aesthetics vertical designed to
transform the physician and consumer experience. The launch further
demonstrates Revance’s commitment to setting new standards through
our products and services.”
We will continue to offer the HintMD fintech platform, the
fintech platform provided by Hint, Inc. at the time it was acquired
by Revance in July 2020, to existing HintMD customers with a phased
migration to OPUL through 2022.
For practices interested in learning more about OPUL™ or to
request a demonstration, please visit OPUL.com.
About Revance
Revance is a biotechnology company focused on innovative
aesthetic and therapeutic offerings, including its next-generation
neuromodulator product, DaxibotulinumtoxinA for Injection.
DaxibotulinumtoxinA for Injection combines a proprietary
stabilizing peptide excipient with a highly purified botulinum
toxin that does not contain human or animal-based components.
Revance has successfully completed a Phase 3 program for
DaxibotulinumtoxinA for Injection in glabellar (frown) lines and is
pursuing U.S. regulatory approval. Revance is also evaluating
DaxibotulinumtoxinA for Injection in the full upper face, including
glabellar lines, forehead lines and crow's feet, as well as in two
therapeutic indications - cervical dystonia and adult upper limb
spasticity. To accompany DaxibotulinumtoxinA for Injection, Revance
owns a unique portfolio of premium products and services for U.S.
aesthetics practices, including the exclusive U.S. distribution
rights to the RHA® Collection of dermal fillers, the first and only
range of FDA-approved fillers for correction of dynamic facial
wrinkles and folds, and the OPUL™ Relational Commerce Platform.
Revance has also partnered with Viatris (formerly Mylan N.V.) to
develop a biosimilar to BOTOX®, which would compete in the existing
short-acting neuromodulator marketplace. Revance is dedicated to
making a difference by transforming patient experiences. For more
information or to join our team visit us at www.revance.com.
“Revance Therapeutics” and the Revance logo are registered
trademarks of Revance Therapeutics, Inc. Resilient Hyaluronic Acid®
and RHA® are trademarks of TEOXANE SA. BOTOX® is a registered
trademark of Allergan, Inc.
Forward Looking Statements
Any statements in this press release that are not statements of
historical fact, including statements related to the potential
benefits to practices and patients of our drug product candidates
and our technologies, including DaxibotulinumtoxinA for Injection,
if approved, the RHA® Collection of dermal fillers and OPUL™; the
needs of aesthetic practices; the rate and degree of commercial
acceptance, opportunity and growth potential of OPUL™; the
aesthetics industry and the size and growth of the aesthetics
market; the growth opportunities available to the company; our
ability to set a new standard in healthcare; differentiation of our
products and services in comparison to our competitors; development
of a biosimilar to BOTOX®; and statements about our business
strategy, timeline and other goals, plans and prospects, constitute
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995, Section 27A of the
Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended. You should not rely
upon forward-looking statements as predictions of future events.
Although we believe that the expectations reflected in the
forward-looking statements are reasonable, we cannot guarantee that
the future results, levels of activity, performance, events,
circumstances or achievements reflected in the forward-looking
statements will ever be achieved or occur.
Forward-looking statements are subject to risks and
uncertainties that could cause actual results to differ materially
from our expectations. These risks and uncertainties relate, but
are not limited to: the results, timing, costs, and completion of
our research and development activities and regulatory approvals,
including the continuing delay in the FDA’s approval of the BLA for
DaxibotulinumtoxinA for Injection for the treatment of glabellar
lines, including as a result of observations made by the FDA during
the site inspection or other reasons; the impact of the COVID-19
pandemic on our manufacturing operations, supply chain, end user
demand for our products, commercialization efforts, business
operations, clinical trials and other aspects of our business and
on the market; our ability to manufacture supplies for our product
candidates and to acquire supplies of the RHA® Collection of dermal
fillers; the uncertain clinical development process; the risk that
clinical trials may not have an effective design or generate
positive results or that positive results would assure regulatory
approval or commercial success; the applicability of clinical study
results to actual outcomes; the rate and degree of economic
benefit, the safety, efficacy, commercial acceptance and the
market, competition, size and growth potential of OPUL™, the RHA®
Collection of dermal fillers and our dug product candidates, if
approved; our ability to continue to successfully commercialize the
RHA® Collection of dermal fillers and OPUL™ and our ability to
successfully commercialize DaxibotulinumtoxinA for Injection, if
approved, and the timing and cost of commercialization activities;
our ability to expand sales and marketing capabilities; the status
of commercial collaborations; our ability to obtain funding for our
operations; the cost and our ability to defend ourselves in product
liability, intellectual property and other lawsuits; our ability to
continue obtaining and maintaining intellectual property protection
for our drug product candidates; our financial performance,
including future revenue, expenses and capital requirements; and
other risks. Detailed information regarding factors that may cause
actual results to differ materially from the results expressed or
implied by statements in this press release may be found in our
periodic filings with the Securities and Exchange Commission (SEC),
including factors described in the section entitled "Risks Factors"
on our Form 10-K filed with the SEC on February 25, 2021 and
including, without limitation, our Form 10-Q for the quarter ended
June 30, 2021, filed with the SEC on August 5, 2021. The
forward-looking statements in this press release speak only as of
the date hereof. We disclaim any obligation to update these
forward-looking statements.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20211011005200/en/
Media Revance Therapeutics, Inc.: Sara Fahy, 949-887-4476
sfahy@revance.com
Investors Revance Therapeutics, Inc.: Jessica Serra,
626-589-1007 Jessica.serra@revance.com
or
Gilmartin Group, LLC.: Laurence Watts, 619-916-7620
laurence@gilmartinir.com
Revance Therapeutics (NASDAQ:RVNC)
Historical Stock Chart
From Jun 2024 to Jul 2024
Revance Therapeutics (NASDAQ:RVNC)
Historical Stock Chart
From Jul 2023 to Jul 2024